A Phase Ic/IIb Study to Evaluate the Efficacy，Safety and Pharmacokinetics of HST in Patients With CHB

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 10, 2022

Primary Completion Date

June 6, 2024

Study Completion Date

December 30, 2024

Conditions

EfficacySafetyPharmacokinetics

Interventions

DRUG

Hepenofovir Fumarate Tablets

Each subject received multiple doses of the test drug/control drug and completed safety, efficacy, and PK evaluations

Trial Locations (1)

RECRUITING

The First Hospital of Jilin University, Jilin

All Listed Sponsors

collaborator

The First Hospital of Jilin University

OTHER

lead

Xi'an Xintong Pharmaceutical Research Co.,Ltd.

OTHER